share_log

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals

解码 Regeneron Pharmicals 的 12 项分析师评估
Benzinga ·  03/26 10:01
12 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals (NASDAQ:REGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在过去的一个季度中,有12位分析师对Regeneron Pharmicals(纳斯达克股票代码:REGN)表达了各种观点,从看涨到看跌,提出了各种各样的观点。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的评级,展示了过去30天情绪的演变,并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1068.58, along with a high estimate of $1184.00 and a low estimate of $850.00. Observing a 3.16% increase, the current average has risen from the previous average price target of $1035.86.
分析师提供了更深入的见解,确定了12个月的目标股价,平均目标价为1068.58美元,最高估计为1184.00美元,低估值为850.00美元。目前的平均价格上涨了3.16%,已从之前的平均目标价1035.86美元上涨。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级:详细明细
An in...
对分...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发